A skin test may help clinicians prevent adverse drug reactions in patients receiving radiocontrast material, according to a new study published in the American Journal of Roentgenology.

A new study found that chronic kidney disease patients who received IV contrast-enhanced imaging faced no more risk of developing contrast-induced nephropathy than those who did not receive contrast material.

The FDA has approved Bayer’s gadobutrol (Gadavist) injection for use in cardiac MRI, making it the first contrast agent approved for the imaging technique, according to a statement from Bayer.

Contrast-enhanced spectral mammography (CESM) can be a helpful method to screen for postoperative breast cancer when paired with traditional mammography, according to research published July 6 in Clinical Radiology.

Dynamic contrast-enhanced (DCE) MRI can help measure the permeability of the blood-brain barrier (BBB) in areas of the brain associated with migraines, potentially providing insight into the debilitating headaches and other neurovascular disorders.

Using contrast agents to enhance CT scans is an established risk factor for kidney injury in those at risk for renal complications, according to a March 23 NPR report, but the research that drove that conclusion years ago might be unbalanced.

Documenting contrast allergies in the electronic health record (EHR) is central for safe imaging, but a new study found such records are incomplete, misleading and often ambiguous. A multidisciplinary approach may be needed to solve the problem.

The International Contrast Ultrasound Society (ICUS) is again urging the FDA to remove the “black box” warning from ultrasound contrast agent (UCA) labels, following its filing of a September 2018 citizen petition with the federal agency.